Last reviewed · How we verify
NCT03387722: SevEos
Assessment of Treatment Patterns of Severe Asthmatic Patients Across the Gulf Region - SevEos Study
trial in Severe Asthma in 253 participants. Completed in 3 January 2019.
3 January 2019
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 253 |
| Start date | 31 December 2017 |
| Primary completion | 3 January 2019 |
| Estimated completion | 3 January 2019 |
| Sites | 2 locations across Oman, United Arab Emirates |
Conditions studied
- Severe Asthma — all drugs for Severe Asthma →
Sponsor
AstraZeneca — full company profile →
Who can join
12 and older, any sex, with Severe Asthma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
SevEos is a cross-sectional, multi-center, non-interventional study aimed to describe the treatment patterns in 250 severe asthma patients across the Gulf region. In addition, the study will determine the current level of asthma control and quality of life in these patients; describe the exacerbation patterns; and determine the current levels of blood eosinophils for the enrolled patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Severe asthma treatment patterns: A multicenter observational study in the Gulf region.
Al-Ahmad M, Mobayed H, Al Busaidi N, Iqbal MN, et al · · 2022 · cited 6× · PMID 35663273 · DOI 10.1016/j.waojou.2022.100647
Verify or expand the search:
- PubMed search for NCT03387722
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Severe Asthma
Currently open trials in the same condition.
- NCT07363642 — Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab · Phase 3 · recruiting
- NCT07328035 — Remission in Adults With Severe Asthma in Thailand · recruiting
- NCT07530770 — Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis · recruiting
- NCT06903780 — Experience of Biologic Treatments for Severe Asthma: a Survey · recruiting
- NCT06681545 — Exploring the Lived Experience of Young Adults With Severe Asthma · recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03387722 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 10 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03387722.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing